Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies
Under science chief Dan Skovronsky, Eli Lilly has taken some big swings at next-gen therapies, including trying to find the next big thing in oncology. Now, after one early failure in the field, Lilly is going back to the bispecific antibody well with a new deal with a Dutch biotech.
Lilly will pay $40 million upfront with an additional $20 million equity stake in Merus NV to identify and develop three bispecific antibodies looking to engage the CD3 antigen on T cells and redirect immune cells, the Indianapolis pharma giant said Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.